Levonorgestrel

Hazard statements (CLP)

H351, H360D, H362

Code

Statements

H351

Suspected of causing cancer

SECTION 2: Hazards identification

2.1 Classification of the substance or mixture

Carcinogenicity, (Category 2) H351: Suspected of causing cancer. Reproductive toxicity, (Category H360D: May damage the unborn child. 1A) Effects on or via lactation H362: May cause harm to breast-fed children.

Signal word

Danger Danger

Hazard statements

H351 Suspected of causing cancer. H360D May damage the unborn child. H362 May cause harm to breast-fed children. H351 Suspected of causing cancer. H362 May cause harm to breast-fed children. H360D May damage the unborn child.

Precautionary statements

P202 Do not handle until all safety precautions have been read and understood. P260 Do not breathe dusts or mists. P263 Avoid contact during pregnancy and while nursing. P264 Wash skin thoroughly after handling. P270 Do not eat, drink or smoke when using this product. P308 + P313 IF exposed or concerned: Get medical advice/ attention. P202 Do not handle until all safety precautions have been read and understood. P308 + P313 IF exposed or concerned: Get medical advice/ attention.

Supplemental label elements

none Reduced Labeling (<= 125 ml) none

Other hazards

This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher

ECOLOGICAL INFORMATION

The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

TOXICOLOGICAL INFORMATION

The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.